Nama's AI scorecard currently rates BridgeBio Pharma Sell (3.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does BBIO report earnings?

BridgeBio Pharma's next scheduled report is on Feb 23, 2027. Analysts expect EPS of -$0.38.

What is the BBIO price target?

The median analyst price target from 20 analysts is $107.50, with a range of $80.00 – $156.00.

Is BBIO Shariah compliant?

Nama's AAOIFI-style screen reads BridgeBio Pharma as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

BridgeBio Pharma (BBIO)

Healthcare · Biotechnology · NASDAQ

BridgeBio Pharma (BBIO) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $14.47B and a free-cash-flow yield of -3.2%. Over the most recent reported fiscal year, revenue grew 126.3%. Nama's AI scorecard rates it Sell, 3.0 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Sell · 3.0/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Middle · +6.0% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-20.5%

How far the last close sits under the highest price of the past five years.

Market cap	$14.47B
Trailing P/E	—
Price / book	—
Price / sales	15.3
FCF yield	-3.2%
Dividend yield	—
Gross margin	94.3%
Operating margin	-37.3%
Net margin	-59.8%
Revenue growth (YoY)	+126.3%
Revenue growth (3-yr annual)	+86.3%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.0
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

BBIO earnings

Next report: Feb 23, 2027 (Q4 2026, EPS estimate -$0.38). Beat the EPS estimate in 1 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 29, 2026	-$0.42	-$0.56	+25.0%	$353.17M
Q2 2026	Aug 10, 2026	-$0.78	-$0.58	-34.5%	$243.68M
Q1 2026	May 7, 2026	-$0.84	-$0.62	-35.5%	$194.51M
Q4 2025	Feb 24, 2026	-$0.94	-$0.62	-51.6%	$154.18M

BBIO analyst price target

Median target $107.50 from 20 analysts, ranging $80.00 – $156.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live BBIO data on Nama Insights →

Recent Congressional trades

BridgeBio Pharma trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Gilbert Cisneros	House	Sell	$1,001 - $15,000	Oct 12, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Jun 8, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	May 8, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Apr 7, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Apr 7, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Apr 7, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Oct 10, 2025
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Sep 12, 2025

BBIO FAQ

Is BBIO a buy?: Nama's AI scorecard currently rates BridgeBio Pharma Sell (3.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does BBIO report earnings?: BridgeBio Pharma's next scheduled report is on Feb 23, 2027. Analysts expect EPS of -$0.38.
What is the BBIO price target?: The median analyst price target from 20 analysts is $107.50, with a range of $80.00 – $156.00.
Is BBIO Shariah compliant?: Nama's AAOIFI-style screen reads BridgeBio Pharma as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.